✦ LIBER ✦

Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone

✍ Scribed by Leonidas Christou; Eleftheria Hatzimichael; Aristidis Chaidos; Stavroula Tsiara; Konstantinos L. Bourantas

Book ID: 114423053
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 60 KB
Volume: 67
Category: Article
ISSN: 0902-4441
DOI: 10.1034/j.1600-0609.2001.067001051.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Benefits and Economic Analysis

Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

✍ Porter, Christopher A.; Rifkin, Robert M. 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 139 KB

IgE plasma cell leukemia successfully tr

IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-α

✍ Noboru Yamagata; Chihiro Shimazaki; Hideo Goto; Toshiyuki Hirata; Eishi Ashihara 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB

Experience with vincristine, doxorubicin

Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald S. Walters; Michael J. Keating; Bart Barlogie; Kenne 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 585 KB

Pegylated liposomal doxorubicin, vincris

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A Phase III multicenter randomized trial

✍ Robert M. Rifkin; Stephanie A. Gregory; Ann Mohrbacher; Mohamad A. Hussein 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

Phase II clinical trial of arsenic triox

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma

✍ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

Intermediate doses of melphalan and dexa

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

✍ J. Vela-Ojeda; M. García-Ruiz Esparza; A. Rosas-Cabral; Y. Padilla-González; J. 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 62 KB